Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer: Results from a randomized adjuvant treatment protocol

L. C. Hartmann, J. N. Ingle, L. E. Wold, G. H. Farr, J. P. Grill, J. Q. Su, N. J. Maihle, J. E. Krook, Thomas Elmer Witzig, P. C. Roche

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Background. This study was designed to evaluate the prognostic importance of c-erbB2 overexpression in a standardized cohort of patients with axillary lymph node positive breast cancer. Methods. Paraffin embedded primary breast cancers from 354 patients with axillary lymph node positive breast cancer, treated on a North Central Cancer Treatment Group adjuvant protocol, were studied immunohistochemically. c-erbB2 staining was classified as negative, weak (1+), moderate (2+), or strong (3+) and was assessed for effectiveness as a predictor of outcome in univariate and Cox model multivariate analyses. Results. Twenty percent of specimens exhibited moderate or strong c-erbB2 staining. The median disease free survival period of the strong staining group was 2.9 years, compared with 7.1 years for all other patients (P = 0.01). The median overall survival for the strong staining group was 5 years, compared with 12 years for all other patients (P = 0.03). A definite correlation was noted between degree of nodal involvement and the likelihood of strong c-erbB2 staining (P = 0.001). There was also a significant correlation between c-erbB2 staining and higher nuclear grade and estrogen receptor negativity. In a multivariate analysis, c-erbB2 staining was not a significant predictor of either disease free survival or overall survival. Conclusion. According to this analysis, the strong correlation between c- erbB2 expression and degree of nodal involvement, higher grade disease, and estrogen receptor negativity suggests expression of this protooncogene product in a biologically more aggressive form of breast cancer. In a multivariate analysis, c-erbB2 expression was not an independent prognostic factor. Thus, c-erbB2 assessment did not appear to add significantly to the information provided by currently available standard disease parameters.

Original languageEnglish (US)
Pages (from-to)2956-2963
Number of pages8
JournalCancer
Volume74
Issue number11
DOIs
StatePublished - 1994

Fingerprint

Clinical Protocols
Lymph Nodes
Staining and Labeling
Breast Neoplasms
Multivariate Analysis
Estrogen Receptors
Disease-Free Survival
Survival
Proportional Hazards Models
Paraffin
Neoplasms

Keywords

  • axillary lymph node positive breast cancer
  • c-erbB2
  • multivariate analysis
  • prognostic factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer : Results from a randomized adjuvant treatment protocol. / Hartmann, L. C.; Ingle, J. N.; Wold, L. E.; Farr, G. H.; Grill, J. P.; Su, J. Q.; Maihle, N. J.; Krook, J. E.; Witzig, Thomas Elmer; Roche, P. C.

In: Cancer, Vol. 74, No. 11, 1994, p. 2956-2963.

Research output: Contribution to journalArticle

Hartmann, L. C. ; Ingle, J. N. ; Wold, L. E. ; Farr, G. H. ; Grill, J. P. ; Su, J. Q. ; Maihle, N. J. ; Krook, J. E. ; Witzig, Thomas Elmer ; Roche, P. C. / Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer : Results from a randomized adjuvant treatment protocol. In: Cancer. 1994 ; Vol. 74, No. 11. pp. 2956-2963.
@article{67e7500357ef4eebbee3a06324401dad,
title = "Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer: Results from a randomized adjuvant treatment protocol",
abstract = "Background. This study was designed to evaluate the prognostic importance of c-erbB2 overexpression in a standardized cohort of patients with axillary lymph node positive breast cancer. Methods. Paraffin embedded primary breast cancers from 354 patients with axillary lymph node positive breast cancer, treated on a North Central Cancer Treatment Group adjuvant protocol, were studied immunohistochemically. c-erbB2 staining was classified as negative, weak (1+), moderate (2+), or strong (3+) and was assessed for effectiveness as a predictor of outcome in univariate and Cox model multivariate analyses. Results. Twenty percent of specimens exhibited moderate or strong c-erbB2 staining. The median disease free survival period of the strong staining group was 2.9 years, compared with 7.1 years for all other patients (P = 0.01). The median overall survival for the strong staining group was 5 years, compared with 12 years for all other patients (P = 0.03). A definite correlation was noted between degree of nodal involvement and the likelihood of strong c-erbB2 staining (P = 0.001). There was also a significant correlation between c-erbB2 staining and higher nuclear grade and estrogen receptor negativity. In a multivariate analysis, c-erbB2 staining was not a significant predictor of either disease free survival or overall survival. Conclusion. According to this analysis, the strong correlation between c- erbB2 expression and degree of nodal involvement, higher grade disease, and estrogen receptor negativity suggests expression of this protooncogene product in a biologically more aggressive form of breast cancer. In a multivariate analysis, c-erbB2 expression was not an independent prognostic factor. Thus, c-erbB2 assessment did not appear to add significantly to the information provided by currently available standard disease parameters.",
keywords = "axillary lymph node positive breast cancer, c-erbB2, multivariate analysis, prognostic factor",
author = "Hartmann, {L. C.} and Ingle, {J. N.} and Wold, {L. E.} and Farr, {G. H.} and Grill, {J. P.} and Su, {J. Q.} and Maihle, {N. J.} and Krook, {J. E.} and Witzig, {Thomas Elmer} and Roche, {P. C.}",
year = "1994",
doi = "10.1002/1097-0142(19941201)74:11<2956::AID-CNCR2820741111>3.0.CO;2-V",
language = "English (US)",
volume = "74",
pages = "2956--2963",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer

T2 - Results from a randomized adjuvant treatment protocol

AU - Hartmann, L. C.

AU - Ingle, J. N.

AU - Wold, L. E.

AU - Farr, G. H.

AU - Grill, J. P.

AU - Su, J. Q.

AU - Maihle, N. J.

AU - Krook, J. E.

AU - Witzig, Thomas Elmer

AU - Roche, P. C.

PY - 1994

Y1 - 1994

N2 - Background. This study was designed to evaluate the prognostic importance of c-erbB2 overexpression in a standardized cohort of patients with axillary lymph node positive breast cancer. Methods. Paraffin embedded primary breast cancers from 354 patients with axillary lymph node positive breast cancer, treated on a North Central Cancer Treatment Group adjuvant protocol, were studied immunohistochemically. c-erbB2 staining was classified as negative, weak (1+), moderate (2+), or strong (3+) and was assessed for effectiveness as a predictor of outcome in univariate and Cox model multivariate analyses. Results. Twenty percent of specimens exhibited moderate or strong c-erbB2 staining. The median disease free survival period of the strong staining group was 2.9 years, compared with 7.1 years for all other patients (P = 0.01). The median overall survival for the strong staining group was 5 years, compared with 12 years for all other patients (P = 0.03). A definite correlation was noted between degree of nodal involvement and the likelihood of strong c-erbB2 staining (P = 0.001). There was also a significant correlation between c-erbB2 staining and higher nuclear grade and estrogen receptor negativity. In a multivariate analysis, c-erbB2 staining was not a significant predictor of either disease free survival or overall survival. Conclusion. According to this analysis, the strong correlation between c- erbB2 expression and degree of nodal involvement, higher grade disease, and estrogen receptor negativity suggests expression of this protooncogene product in a biologically more aggressive form of breast cancer. In a multivariate analysis, c-erbB2 expression was not an independent prognostic factor. Thus, c-erbB2 assessment did not appear to add significantly to the information provided by currently available standard disease parameters.

AB - Background. This study was designed to evaluate the prognostic importance of c-erbB2 overexpression in a standardized cohort of patients with axillary lymph node positive breast cancer. Methods. Paraffin embedded primary breast cancers from 354 patients with axillary lymph node positive breast cancer, treated on a North Central Cancer Treatment Group adjuvant protocol, were studied immunohistochemically. c-erbB2 staining was classified as negative, weak (1+), moderate (2+), or strong (3+) and was assessed for effectiveness as a predictor of outcome in univariate and Cox model multivariate analyses. Results. Twenty percent of specimens exhibited moderate or strong c-erbB2 staining. The median disease free survival period of the strong staining group was 2.9 years, compared with 7.1 years for all other patients (P = 0.01). The median overall survival for the strong staining group was 5 years, compared with 12 years for all other patients (P = 0.03). A definite correlation was noted between degree of nodal involvement and the likelihood of strong c-erbB2 staining (P = 0.001). There was also a significant correlation between c-erbB2 staining and higher nuclear grade and estrogen receptor negativity. In a multivariate analysis, c-erbB2 staining was not a significant predictor of either disease free survival or overall survival. Conclusion. According to this analysis, the strong correlation between c- erbB2 expression and degree of nodal involvement, higher grade disease, and estrogen receptor negativity suggests expression of this protooncogene product in a biologically more aggressive form of breast cancer. In a multivariate analysis, c-erbB2 expression was not an independent prognostic factor. Thus, c-erbB2 assessment did not appear to add significantly to the information provided by currently available standard disease parameters.

KW - axillary lymph node positive breast cancer

KW - c-erbB2

KW - multivariate analysis

KW - prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=0028143956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028143956&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19941201)74:11<2956::AID-CNCR2820741111>3.0.CO;2-V

DO - 10.1002/1097-0142(19941201)74:11<2956::AID-CNCR2820741111>3.0.CO;2-V

M3 - Article

C2 - 7954259

AN - SCOPUS:0028143956

VL - 74

SP - 2956

EP - 2963

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -